Commerzbank Aktiengesellschaft FI Acquires 14,693 Shares of Amgen Inc. $AMGN

Key Points

• Commerzbank Aktiengesellschaft FI increased its Amgen stake by 7.5%, buying 14,693 shares to reach 209,478 shares valued at approximately $75.9 million. Institutional investors collectively own 76.5% of AMGN.
• Amgen reported strong quarterly results, with revenue up 9.5% year over year to $10.05 billion and EPS of $6.29, beating estimates. The company guided for fiscal 2026 EPS of $22.30–$23.50 and declared a quarterly dividend of $2.52, implying a 2.4% annualized yield.
• Analyst sentiment remains mixed: the consensus rating is Hold with a $375.93 price target, while recent targets range from $317 to $450. Meanwhile, insiders sold 6,222 shares worth about $2.54 million over the past 90 days.

Commerzbank Aktiengesellschaft FI lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 209,478 shares of the medical research company's stock after purchasing an additional 14,693 shares during the quarter. Amgen accounts for approximately 1.5% of Commerzbank Aktiengesellschaft FI's portfolio, making the stock its 22nd largest position. Commerzbank Aktiengesellschaft FI's holdings in Amgen were worth $75,856,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of AMGN. Dogwood Wealth Management LLC increased its holdings in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock worth $25,000 after buying an additional 55 shares during the last quarter. Anfield Capital Management LLC lifted its holdings in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after acquiring an additional 70 shares during the last quarter. Tower View Wealth Management LLC lifted its holdings in shares of Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock worth $29,000 after acquiring an additional 63 shares during the last quarter. Manning & Napier Advisors LLC grew its position in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new position in Amgen in the fourth quarter worth $34,000. 76.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

AMGN has been the topic of a number of research reports. Bank of America raised their price target on Amgen from $312.00 to $317.00 and gave the company an "underperform" rating in a research report on Wednesday, August 5th. Mizuho upped their price objective on Amgen from $303.00 to $352.00 and gave the stock a "neutral" rating in a report on Tuesday. UBS Group increased their price objective on Amgen from $420.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Barclays raised their price objective on Amgen from $360.00 to $380.00 and gave the company an "equal weight" rating in a report on Friday. Finally, BMO Capital Markets boosted their target price on Amgen from $400.00 to $450.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $375.93.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company's stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 over the last ninety days. Insiders own 0.85% of the company's stock.

Amgen Stock Performance

NASDAQ AMGN opened at $425.28 on Wednesday. The company has a 50-day simple moving average of $373.66 and a two-hundred day simple moving average of $360.06. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $427.39. The firm has a market cap of $229.92 billion, a price-to-earnings ratio of 26.43, a PEG ratio of 3.86 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company's quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts forecast that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen's payout ratio is 62.65%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent results reinforced its growth narrative: quarterly revenue rose 9.5% year over year to $10.05 billion, while adjusted earnings of $6.29 per share exceeded consensus by $0.67. Management’s fiscal 2026 EPS guidance of $22.30–$23.50 also supports the bullish outlook. Amgen Results Put Growth Back in Focus
• Positive Sentiment: A completed Phase 1 study comparing two evolocumab formulations provides continued support for Amgen’s cholesterol franchise. Evolocumab, marketed as Repatha, is an important commercial product, and formulation work could help support its future development and patient use. Amgen’s Evolocumab Formulation Study
• Positive Sentiment: Growth-focused analysis from Zacks highlights Amgen’s earnings profile and potential for continued performance, adding to the favorable investor narrative. Why Amgen Is a Strong Growth Stock
• Neutral Sentiment: Cantor Fitzgerald raised its Amgen price target to $400 but retained a Neutral rating. Mizuho also maintained Neutral while lifting its target to $352, indicating that analysts see some fundamental improvement but believe the recent rally has exceeded their valuation expectations.
• Negative Sentiment: Amgen exercised its right to terminate a partnership with TScan Therapeutics, removing a collaboration from TScan’s pipeline. While the direct financial effect on Amgen is unclear, the termination may raise questions about partnership prioritization or the development prospects of the related program. TScan Therapeutics Faces Loss of Key Amgen Partnership

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source